Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
881.1 USD | -1.08% | -1.28% | +0.80% |
02:45pm | Oppenheimer Adjusts Price Target on Regeneron Pharmaceuticals to $1,175 From $1,125 | MT |
Apr. 25 | Regeneron Pharmaceuticals Receives a Shareholder Proposal from John Chevedden | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.80% | 95.71B | |
-2.35% | 103B | |
+2.01% | 22.02B | |
-16.53% | 20.9B | |
-8.91% | 17.85B | |
-42.83% | 16.21B | |
-14.86% | 15.52B | |
+3.35% | 13.86B | |
+34.41% | 12.04B | |
-26.05% | 8.08B |
- Stock Market
- Equities
- REGN Stock
- News Regeneron Pharmaceuticals, Inc.
- Regeneron Pharmaceuticals' Biologics License Application Review for COVID-19 Treatment REGEN-COV Extended by FDA